Background and Aim: Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract. Although various biomarkers have been used to predict infliximab (IFX) response in CD, its efficacy in patients with small bowel involvement remains underexplored. This study combined clinical ...
ORGANISM(S): Homo sapiens (Human)
